Navigation Links
SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
Date:1/3/2012

WASHINGTON, LONDON and HONG KONG, Jan. 3, 2012 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, announced that Neil J. Campbell, President and CEO, will present a corporate and technology overview at Biotech Showcase 2012 in San Francisco, CA.  Mr. Campbell's presentation is scheduled for Monday, January 9, 2012 at 4:45pm in the Stockton Room at the Parc 55 Wyndham Union Square Hotel.

The presentation will include an overview of SuperNova's proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology, targeted for four industry sectors: human health, animal health, industrial and biodefense / biosecurity; as well as provide additional details on the company's recent commercial partnership with Concile, GmbH.

"Biotech Showcase is the premier event for investors and business leaders in the healthcare industry, and is an ideal opportunity for SuperNova to feature its 'lab-in-the-palm-of-your-hand' diagnostic system," said Mr. Campbell.  "With our AmpCrystal® platform, which provides an array of diagnostic capabilities at point of interest settings in human and non-human applications as well as improving central laboratory assays, SuperNova is well poised to capture the multi-billion dollar point-of-care and general diagnostic markets." 

About SuperNova Diagnostics®, Inc.
SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications.  A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements.  SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® — Putting the Laboratory in the Palm of Your Hand®.  For additional information, please visit www.supernovadiagnostics.com.

Contacts:
Tiberend Strategic Advisors, Inc.
Jason Rando / June Gregg
(212) 827-0020
jrando@tiberend.com / jgregg@tiberend.com


'/>"/>
SOURCE SuperNova Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
2. SuperNova Diagnostics® to Present at AdvaMed 2011: The Medtech Conference in Washington, D.C.
3. SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011
4. SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics
5. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
6. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
7. ShangPharma to Present at J.P. Morgans 30th Annual Healthcare Conference
8. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
9. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
10. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology Center, Inc. ... bio and technology start-ups, is hosting “Celebration Friday” (a festive gathering highlighting client ... with libations and networking at 3:30 p.m. at FITCI’s 4539 Metropolitan Court location, ...
(Date:4/20/2017)... ... April 20, 2017 , ... As part of ... explore challenging patient cases when screening for direct oral anticoagulant. When patients taking ... need for bridging parental anticoagulation especially for those at high risk of thrombosis ...
(Date:4/20/2017)... 20, 2017  Eli Lilly and Company (NYSE: ... galcanezumab for the prevention of migraine at the American ... place April 22-28, 2017, in Boston ... at AAN, including safety and patient outcomes data for ... a reduction in monthly migraine headache days among patients ...
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... to the scientific and clinical research community’s growing body of knowledge during its ... in the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):